Abstract
Backgound: Since nucleos(t)ide Analogues (NA) suppress viral replication in HBeAg-negative CHB without inducing significantly HBsAg loss, several studies are investigating the impact to HBsAg levels of Peginterferon alfa-2a (PEG-IFN) addition to NA treated patients. Here we present the week 24 analysis of an ongoing trial evaluating PEG-IFN add-on in NA treated CHB, HBeAg-negative, genotype D, Caucasians patients (HERMES study). Methods: In this phase IIb, open label, single arm, multicenter Italian study, patients who were receiving NA monotherapy, with HBV-DNA persistently below 20 IU/ml for at least 12 months and HBsAg>100 IU/ml, initiated add-on treatment with Peginterferon alfa-2a 180μg sc once weekly for 48 weeks.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
